Global status of Toxoplasma gondii infection and associated risk factors in people living with HIV
-
- Hanie Safarpour
- Infectious and Tropical Diseases Research Center
-
- Muge Cevik
- Division of Infection and Global Health Research, School of Medicine, University of St Andrews, Fife, UK
-
- Mehdi Zarean
- Department of Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
-
- Aleksandra Barac
- Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia
-
- Kareem Hatam-Nahavandi
- Iranshahr University of Medical Sciences, Iranshahr
-
- Mohammad T. Rahimi
- School of Medicine, Shahroud University of Medical Sciences, Shahroud
-
- Hossein Bannazadeh Baghi
- Immunology Research Center
-
- Tohid J. Koshki
- Department of Statistics and Epidemiology, Faculty of Health and Nutrition, Tabriz University of Medical Sciences, Tabriz
-
- Abdol S. Pagheh
- Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand
-
- Firooz Shahrivar
- Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran
-
- Mina Ebrahimi
- Research Center for Evidence Based Medicine (RCEBM), Tabriz University of Medical Sciences, Tabriz, Iran.
-
- Ehsan Ahmadpour
- Research Center for Evidence Based Medicine (RCEBM), Tabriz University of Medical Sciences, Tabriz, Iran.
この論文をさがす
説明
<jats:sec> <jats:title>Objective:</jats:title> <jats:p> <jats:italic toggle="yes">Toxoplasma</jats:italic> infection remains as the most common cause of focal brain lesions among people living with HIV (PLHIV) despite the decline in opportunistic infections with the introduction of antiretroviral treatment. This study was conducted to provide a summary of evidence about the seroprevalence of <jats:italic toggle="yes">Toxoplasma gondii</jats:italic> and prevalence of active <jats:italic toggle="yes">T. gondii</jats:italic> infection and associated risk factors among PLHIV.</jats:p> </jats:sec> <jats:sec> <jats:title>Design:</jats:title> <jats:p>Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Scopus, PubMed, Science Direct and EMBASE were searched from <jats:italic toggle="yes">1997 to July 2018.</jats:italic> All peer-reviewed original research articles describing <jats:italic toggle="yes">T. gondii</jats:italic> infection among PLHIV with different diagnostic methods were included.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>Incoherence and heterogeneity between studies were quantified by <jats:italic toggle="yes">I</jats:italic> <jats:sup>2</jats:sup> index and Cochran's <jats:italic toggle="yes">Q</jats:italic> test. Publication and population bias were assessed with funnel plots and Egger's regression asymmetry test. All statistical analyses were performed using StatsDirect.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>In total, 111 studies from 37 countries assessing 66 139 blood samples were included in this study. The pooled prevalence of <jats:italic toggle="yes">T. gondii</jats:italic> infection among PLHIV was 3.24% by IgM and 26.22% by molecular methods using the random-effects model. Pooled seroprevalence of <jats:italic toggle="yes">T. gondii</jats:italic> by IgG was 44.22%. There was a relationship between <jats:italic toggle="yes">Toxoplasma</jats:italic> prevalence and sex, raw meat consumption, contact with cat and knowledge about toxoplasmosis.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>High <jats:italic toggle="yes">Toxoplasma</jats:italic> seroprevalence among PLHIV observed in this study emphasizes the need for implementing screening and prophylaxis tailored to the local context. Owing to the serious and significant clinical manifestations of the parasite in case of reactivation, early identification of seropositivity for initiating prophylaxis among those with a CD4<jats:sup>+</jats:sup> cell count of less than 200 cells/ml is recommended.</jats:p> </jats:sec>
収録刊行物
-
- AIDS
-
AIDS 34 (3), 469-474, 2020-03-01
Ovid Technologies (Wolters Kluwer Health)